Developer docs
API playgroundTry for free, no card

Search company profiles

Epitopea

Full company profile

uuid00006vr

Namestring
Epitopea
Legal namestring
Epitopea Limited
Websiteurl
epitopea.com
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapies, RNA therapeutics, tumor antigens, therapeutic vaccines, antigen discovery
Industry3 codes
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Immunotherapies
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1RNA Immunotherapy Pipeline
TypeLicensing Royalties
Description

Epitopea is a pre-revenue clinical-stage biotech company developing a pipeline of RNA-based cancer immunotherapies. Revenue will be generated through eventual product sales upon regulatory approval, as well as through milestone payments and royalties from strategic partnerships and licensing agreements.

globenewswire.com
2Strategic Partnerships & Collaborations
TypeLicensing Royalties
Description

Revenue through research collaboration payments, upfront fees, milestone payments (up to $300M per product with MSD), and potential royalties from developed therapeutics.

epitopea.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1CryptoMap
Description

Proprietary discovery platform that identifies shared, aberrantly expressed tumor-specific antigens (aeTSAs) called Cryptigen TSAs, using spatial immunopeptidomics, genomics, and systems bioinformatics.

epitopea.com
+2 more records
Core offering1 text field

Epitopea develops off-the-shelf RNA-based cancer immunotherapies targeting novel tumor-specific antigens called Cryptigens. Its proprietary CryptoMap discovery platform uses spatial immunopeptidomics, genomics, and bioinformatics to identify approximately 100 aberrantly expressed tumor-specific antigens (aeTSAs) per tumor type that are shared across patients. These Cryptigen TSAs feed into the CryptiVax pipeline of mRNA therapeutic vaccines, with lead candidate CryptiVax-1001 in Phase I/Ib clinical development for high-grade serous ovarian cancer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • OVACT Phase I/Ib clinical trial approved by MHRA and Regional Ethics Committee for CryptiVax-1001 in advanced high-grade serous ovarian cancer
+2 more records
Product overview1 text field

Epitopea operates as a platform-driven biotech company developing off-the-shelf RNA-based cancer immunotherapies. The company's core offering is the CryptoMap™ discovery platform, which identifies shared aberrantly expressed tumor-specific antigens called Cryptigen™ TSAs hidden in cancer's 'junk DNA'. These Cryptigen™ TSAs feed into the CryptiVax™ pipeline, the company's most advanced candidate being CryptiVax-1001, an mRNA therapeutic vaccine currently in Phase I/Ib clinical development for high-grade serous ovarian cancer. The platform enables identification of approximately 100 antigens per tumor type, supporting broad patient coverage with off-the-shelf treatments.

Product and service3 records
1CryptoMap™ discovery platform
CategoryAntigen discovery platform
Description

Proprietary discovery platform that identifies shared, aberrantly expressed tumor-specific antigens (aeTSAs), known as Cryptigen™ TSAs, using spatial immunopeptidomics, genomics, and systems bioinformatics. The platform identifies approximately 100 aberrantly expressed tumor-specific antigens per tumor type. Licensed to strategic partners such as MSD (Merck) for the discovery of Cryptigen TSAs in undisclosed solid tumor indications.

2CryptiVax-1001
CategorymRNA therapeutic vaccine (lead clinical candidate)
Description

Lead off-the-shelf mRNA therapeutic vaccine targeting advanced high-grade serous ovarian cancer (HGSOC). Currently in Phase I/Ib clinical trial (OVACT) evaluating safety, tolerability, immunogenicity, and early clinical activity in HRP+/BRCA-wildtype patients. Designed to drive targeted immune responses using Cryptigen tumor-specific antigens chosen for broad patient coverage.

3CryptiVax™ pipeline
CategoryCancer immunotherapy pipeline
Description

Pipeline of RNA-based cancer immunotherapeutics (including therapeutic vaccines, T cell receptor-based therapies, and other modalities) utilizing Cryptigen™ TSAs as targets for hard-to-treat solid tumors such as ovarian and lung cancer.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-19
Description

License and research collaboration agreement for identification of Cryptigen tumor-specific antigens in an undisclosed solid tumor. Epitopea deploys CryptoMap platform to identify novel Cryptigen TSAs. MSD has exclusive rights to develop and commercialize therapeutics. Epitopea receives undisclosed upfront payment and is eligible for milestone payments up to $300 million per product.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-12-19
Description

Collaboration and non-exclusive license agreement for lipid nanoparticle (LNP) delivery technology. Genevant grants Epitopea worldwide non-exclusive license for LNP technology to develop mRNA-LNP immunotherapies targeting Cryptigen TSAs for an undisclosed oncology indication. Genevant eligible for up to $123.5 million per product in upfront and milestone payments plus royalties.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-26
Description

Collaborative research project between Epitopea and Université de Montréal to develop and validate CryptoMap platform. Funded by $1,499,457 CAD grant from Quebec government. Project aims to identify novel Cryptigen sets from patients with diverse origins for universal RNA cancer vaccines targeting lung and ovarian cancers.

Strategic tierCoreTypeTechnology or Integration
Description

Exclusive license for CryptoMap platform technology developed by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer (IRIC). Research collaboration for continued platform development and validation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Moderna is the leading mRNA therapeutics company and a direct competitor in mRNA-based cancer vaccines (e.g., mRNA-4157/V940 in melanoma). Its Intis Meranmod platform and extensive oncology pipeline compete head-to-head with Epitopea's RNA cancer vaccine approach.

TypeDirect peer
Description

BioNTech is a pioneer in mRNA cancer vaccines (including individualized neoantigen programs like BNT122) and shares Epitopea's strategic positioning around RNA-based immuno-oncology. Comparable platform business model with pharma partnerships and internal pipeline assets.

TypeDirect peer
Description

CureVac is an mRNA technology company developing cancer vaccines and other RNA-based therapeutics. Klaus Edvardsen (Epitopea's CMO) previously led development at CureVac, and the companies pursue overlapping cancer immunotherapy modalities.

TypeDirect peer
Description

Nykode is a clinical-stage Norwegian biotech developing off-the-shelf therapeutic cancer vaccines using its modular Vaccibody DNA/plasmid platform. Klaus Edvardsen was previously Chief Development Officer at Nykode, and the company is directly comparable in modality and clinical stage.

TypeDirect peer
Description

Gritstone bio develops neoantigen-based cancer vaccines (e.g., GRANITE and SLATE programs) using self-amplifying RNA and chimpanzee adenovirus delivery. Comparable therapeutic modality and tumor-specific antigen targeting strategy.

6Elicio Therapeutics
TypeEmerging player
Description

Elicio is a clinical-stage company developing AMP-platform cancer vaccines that deliver immunogens to lymph nodes, with overlapping focus on tumor-specific antigen vaccines for solid tumors. Smaller and earlier-stage than Epitopea but directly comparable in cancer vaccine modality.

TypeBroad incumbent
Description

Genmab is an established antibody-based immuno-oncology company (with products including bispecifics like epcoritamab). Klaus Edvardsen previously held a senior oncology role at Genmab, and the company represents a broad incumbent in immuno-oncology adjacent to Epitopea's RNA cancer vaccine space.

TypeBroad incumbent
Description

Merck KGaA is a diversified life-sciences and pharma incumbent with significant oncology R&D. Klaus Edvardsen was previously SVP, Head of Global Oncology Development at Merck KgaA; the company is a broad incumbent whose mRNA/cancer vaccine efforts overlap Epitopea's competitive space.

TypeBroad incumbent
Description

AstraZeneca is a top-tier oncology pharma whose approved checkpoint inhibitors and ADCs (Imfinzi, Enhertu) and active cancer vaccine programs (e.g., the Boehringer Ingelheim/Genmab partnership) make it a broad incumbent comparable to Epitopea's large-pharma counterparties.

TypeEmerging player
Description

Nouscom is a clinical-stage biotech developing off-the-shelf neoantigen cancer vaccines using viral vectors and a similar shared-antigen discovery approach. Comparable clinical stage, modality, and target patient population to Epitopea's CryptiVax pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Epitopea

Cancer Immunotherapiesepitopea.com

Epitopea firmographics

Firmographics
Name
Epitopea
Legal name
Epitopea Limited
Website
https://epitopea.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Epitopea industry classification

Industry
Product category
Cancer Immunotherapies
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)

Keywords

  • Cancer immunotherapies
  • RNA therapeutics
  • Tumor antigens
  • Therapeutic vaccines
  • Antigen discovery

Where Epitopea is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Epitopea business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. RNA Immunotherapy Pipeline: Epitopea is a pre-revenue clinical-stage biotech company developing a pipeline of RNA-based cancer immunotherapies. Revenue will be generated through eventual product sales upon regulatory approval, as well as through milestone payments and royalties from strategic partnerships and licensing agreements.
  2. Strategic Partnerships & Collaborations: Revenue through research collaboration payments, upfront fees, milestone payments (up to $300M per product with MSD), and potential royalties from developed therapeutics.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Epitopea product offering

Product offering

Core offering

Epitopea develops off-the-shelf RNA-based cancer immunotherapies targeting novel tumor-specific antigens called Cryptigens. Its proprietary CryptoMap discovery platform uses spatial immunopeptidomics, genomics, and bioinformatics to identify approximately 100 aberrantly expressed tumor-specific antigens (aeTSAs) per tumor type that are shared across patients. These Cryptigen TSAs feed into the CryptiVax pipeline of mRNA therapeutic vaccines, with lead candidate CryptiVax-1001 in Phase I/Ib clinical development for high-grade serous ovarian cancer.

Product overview

Epitopea operates as a platform-driven biotech company developing off-the-shelf RNA-based cancer immunotherapies. The company's core offering is the CryptoMap™ discovery platform, which identifies shared aberrantly expressed tumor-specific antigens called Cryptigen™ TSAs hidden in cancer's 'junk DNA'. These Cryptigen™ TSAs feed into the CryptiVax™ pipeline, the company's most advanced candidate being CryptiVax-1001, an mRNA therapeutic vaccine currently in Phase I/Ib clinical development for high-grade serous ovarian cancer. The platform enables identification of approximately 100 antigens per tumor type, supporting broad patient coverage with off-the-shelf treatments.

Differentiator

Problem solved

Functional benefit

Brands

  • CryptoMap: Proprietary discovery platform that identifies shared, aberrantly expressed tumor-specific antigens (aeTSAs) called Cryptigen TSAs, using spatial immunopeptidomics, genomics, and systems bioinformatics.
  • Cryptigen
  • CryptiVax

Products and services

  • CryptoMap™ discovery platform Proprietary discovery platform that identifies shared, aberrantly expressed tumor-specific antigens (aeTSAs), known as Cryptigen™ TSAs, using spatial immunopeptidomics, genomics, and systems bioinformatics. The platform identifies approximately 100 aberrantly expressed tumor-specific antigens per tumor type. Licensed to strategic partners such as MSD (Merck) for the discovery of Cryptigen TSAs in undisclosed solid tumor indications.
  • CryptiVax-1001 Lead off-the-shelf mRNA therapeutic vaccine targeting advanced high-grade serous ovarian cancer (HGSOC). Currently in Phase I/Ib clinical trial (OVACT) evaluating safety, tolerability, immunogenicity, and early clinical activity in HRP+/BRCA-wildtype patients. Designed to drive targeted immune responses using Cryptigen tumor-specific antigens chosen for broad patient coverage.
  • CryptiVax™ pipeline Pipeline of RNA-based cancer immunotherapeutics (including therapeutic vaccines, T cell receptor-based therapies, and other modalities) utilizing Cryptigen™ TSAs as targets for hard-to-treat solid tumors such as ovarian and lung cancer.

Quantifiable outcome

  • OVACT Phase I/Ib clinical trial approved by MHRA and Regional Ethics Committee for CryptiVax-1001 in advanced high-grade serous ovarian cancer
  • +2 more outcomes

Companies that use Epitopea

Customer profile

Segments2 records

Ideal customer profiles2 records

Epitopea technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Epitopea partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • MSD (Merck)coreStrategic or Co-development Partner · 19 February 2025License and research collaboration agreement for identification of Cryptigen tumor-specific antigens in an undisclosed solid tumor. Epitopea deploys CryptoMap platform to identify novel Cryptigen TSAs. MSD has exclusive rights to develop and commercialize therapeutics. Epitopea receives undisclosed upfront payment and is eligible for milestone payments up to $300 million per product.
  • Genevant SciencescoreTechnology or Integration · 19 December 2024Collaboration and non-exclusive license agreement for lipid nanoparticle (LNP) delivery technology. Genevant grants Epitopea worldwide non-exclusive license for LNP technology to develop mRNA-LNP immunotherapies targeting Cryptigen TSAs for an undisclosed oncology indication. Genevant eligible for up to $123.5 million per product in upfront and milestone payments plus royalties.
  • CQDMcoreStrategic or Co-development Partner · 26 September 2024Collaborative research project between Epitopea and Université de Montréal to develop and validate CryptoMap platform. Funded by $1,499,457 CAD grant from Quebec government. Project aims to identify novel Cryptigen sets from patients with diverse origins for universal RNA cancer vaccines targeting lung and ovarian cancers.
  • Université de MontréalcoreTechnology or IntegrationExclusive license for CryptoMap platform technology developed by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer (IRIC). Research collaboration for continued platform development and validation.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Epitopea competitors and assessment

Company assessment

Direct peers

  • Moderna: Moderna is the leading mRNA therapeutics company and a direct competitor in mRNA-based cancer vaccines (e.g., mRNA-4157/V940 in melanoma). Its Intis Meranmod platform and extensive oncology pipeline compete head-to-head with Epitopea's RNA cancer vaccine approach.
  • BioNTech: BioNTech is a pioneer in mRNA cancer vaccines (including individualized neoantigen programs like BNT122) and shares Epitopea's strategic positioning around RNA-based immuno-oncology. Comparable platform business model with pharma partnerships and internal pipeline assets.
  • CureVac: CureVac is an mRNA technology company developing cancer vaccines and other RNA-based therapeutics. Klaus Edvardsen (Epitopea's CMO) previously led development at CureVac, and the companies pursue overlapping cancer immunotherapy modalities.
  • Nykode Therapeutics: Nykode is a clinical-stage Norwegian biotech developing off-the-shelf therapeutic cancer vaccines using its modular Vaccibody DNA/plasmid platform. Klaus Edvardsen was previously Chief Development Officer at Nykode, and the company is directly comparable in modality and clinical stage.
  • Gritstone bio: Gritstone bio develops neoantigen-based cancer vaccines (e.g., GRANITE and SLATE programs) using self-amplifying RNA and chimpanzee adenovirus delivery. Comparable therapeutic modality and tumor-specific antigen targeting strategy.

Emerging players

  • Elicio Therapeutics: Elicio is a clinical-stage company developing AMP-platform cancer vaccines that deliver immunogens to lymph nodes, with overlapping focus on tumor-specific antigen vaccines for solid tumors. Smaller and earlier-stage than Epitopea but directly comparable in cancer vaccine modality.
  • Nouscom: Nouscom is a clinical-stage biotech developing off-the-shelf neoantigen cancer vaccines using viral vectors and a similar shared-antigen discovery approach. Comparable clinical stage, modality, and target patient population to Epitopea's CryptiVax pipeline.

Broad incumbents

  • Genmab: Genmab is an established antibody-based immuno-oncology company (with products including bispecifics like epcoritamab). Klaus Edvardsen previously held a senior oncology role at Genmab, and the company represents a broad incumbent in immuno-oncology adjacent to Epitopea's RNA cancer vaccine space.
  • Merck KGaA: Merck KGaA is a diversified life-sciences and pharma incumbent with significant oncology R&D. Klaus Edvardsen was previously SVP, Head of Global Oncology Development at Merck KgaA; the company is a broad incumbent whose mRNA/cancer vaccine efforts overlap Epitopea's competitive space.
  • AstraZeneca: AstraZeneca is a top-tier oncology pharma whose approved checkpoint inhibitors and ADCs (Imfinzi, Enhertu) and active cancer vaccine programs (e.g., the Boehringer Ingelheim/Genmab partnership) make it a broad incumbent comparable to Epitopea's large-pharma counterparties.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Epitopea social profiles

Digital presence

Epitopea financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Epitopea leadership team

Management profile

Number of profiles

Profiles5 records

Epitopea funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Epitopea M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epitopea

What does Epitopea do?

Epitopea develops off-the-shelf RNA-based cancer immunotherapies targeting novel tumor-specific antigens called Cryptigens. Its proprietary CryptoMap discovery platform uses spatial immunopeptidomics, genomics, and bioinformatics to identify approximately 100 aberrantly expressed tumor-specific antigens (aeTSAs) per tumor type that are shared across patients. These Cryptigen TSAs feed into the CryptiVax pipeline of mRNA therapeutic vaccines, with lead candidate CryptiVax-1001 in Phase I/Ib clinical development for high-grade serous ovarian cancer.

Is Epitopea a public or private company?

Epitopea is a private company. It is classified as venture growth investor backed and is currently operating.

When was Epitopea founded?

Epitopea was founded in 2021. It employs 11 to 50 people.

Where is Epitopea based?

Epitopea is headquartered in Montreal, Canada, in the North America region.

How does Epitopea make money?

Two revenue lines are on record. RNA Immunotherapy Pipeline is the primary driver. The others are strategic Partnerships & Collaborations.

Who are Epitopea's main competitors?

Direct peers on record are Moderna, BioNTech, CureVac, Nykode Therapeutics and Gritstone bio. Emerging players are Elicio Therapeutics and Nouscom. Broad incumbents are Genmab, Merck KGaA and AstraZeneca.

Does Epitopea have an API?

No public API is recorded for Epitopea.

What industry is Epitopea in?

Epitopea's product category is Cancer Immunotherapies. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialEpitopea Announces First Patient Dosed In OVACT Phase 1/1B Clinical Trial Of Cryptivaxtm-1001 In Advanced High-Grade Serous Ovarian CancerEpitopea announced the first patient dosed in its OVACT Phase 1/1B trial of CryptiVax-1001 for advanced high-grade serous ovarian cancer. The trial enrolls up to 30 women across 10 UK centers to evaluate safety and early activity. The vaccine targets tumor-specific antigens for patients with limited treatment options.GlobeNewswireEpitopea Announces First Patient Dosed in OVACT Phase 1/1b Clinical Trial of CryptiVax™-1001 in Advanced High-Grade Serous Ovarian CancerEpitopea announced the first patient was dosed in its Phase 1/1b OVACT trial of CryptiVax-1001 for advanced high-grade serous ovarian cancer. The trial enrolls up to 30 women across 10 UK centers to evaluate safety and early activity. The company aims to provide durable treatment for this underserved population.GlobeNewswireEpitopea annonce l'administration de la première dose à une patiente dans le cadre de l'essai clinique OVACT de phase 1/1b portant sur le CryptiVaxTM-1001 dans le cancer de l'ovaire séreux de haut grade avancéEpitopea announced the first patient received CryptiVax-1001 in its phase 1/1b OVACT trial for advanced high-grade serous ovarian cancer. The trial enrolls up to 30 women in up to 10 UK centers, targeting HRP+/BRCA wild-type patients. The company aims to offer durable immunotherapy options for this population.European BiotechnologyRNA medicine enters its ­second actRNA therapeutics are expanding beyond mRNA vaccines into oncology, cardiovascular, and autoimmune diseases, with siRNA medicines already generating billions in revenue. Delivery systems and new modalities like microRNA are key, and Europe sees room for innovation despite US leadership.Clinical Trials ArenaEpitopea receives MHRA and REC approvals for OVACT ovarian cancer trialEpitopea received MHRA and REC approval for its OVACT trial of CryptiVax-1001, an RNA-based vaccine for advanced high-grade serous ovarian cancer. The Phase I/Ib trial will assess immunogenicity, safety, and early clinical data in HR-proficient/BRCA-wildtype patients. Susana Banerjee is named chief investigator.Financial PostEpitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian CancerEpitopea announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the Regional Ethics Committee (REC) have approved its clinical trial application (CTA) for the OVACT Phase 1/1b trial of CryptiVax-1001, the company's lead program targeting advanced high-grade serous ovarian cancer. The company also appointed Professor Susana Banerjee of The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research as Chief Investigator for the trial. High-grade serous ovarian cancer represents one of the most difficult-to-treat solid tumors, with roughly 80% of patients presenting with advanced or metastatic disease, and HRP+/BRCA-wildtype patients—who comprise approximately half the ovarian cancer population—currently face a significant therapeutic gap with limited maintenance options.GlobeNewswireEpitopea Announces Approval of OVACT Clinical TrialEpitopea received MHRA and REC approval for its OVACT clinical trial of CryptiVax-1001 for high-grade serous ovarian cancer. The Phase 1/1b trial will evaluate safety and early activity in HRP+/BRCA-wildtype patients. Professor Susana Banerjee was appointed Chief Investigator.European BiotechnologyEpitopea wins UK approval for therapeutic vaccine trialEpitopea received UK regulatory approval for its OVACT trial of CryptiVax-1001, a first-in-human RNA-based vaccine for advanced high-grade serous ovarian cancer. The Phase I/Ib study will assess safety, tolerability, immunogenicity, and early activity in HRP+/BRCA-wildtype patients. The company aims to develop off-the-shelf mRNA immunotherapies with broad patient coverage.BioSpaceEpitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian CancerEpitopea received MHRA and REC approval for its OVACT clinical trial of CryptiVax-1001 in advanced high-grade serous ovarian cancer. The Phase 1/1b trial will evaluate safety and early activity in HRP+/BRCA-wildtype patients, with Professor Susana Banerjee appointed as Chief Investigator.Financial PostEpitopea Strengthens Scientific Advisory Board with Appointment of Leading Authority in Cancer, Lisa ButterfieldEpitopea, a transatlantic cancer immunotherapeutics company, announced the appointment of Lisa Butterfield to its Scientific Advisory Board. Dr. Butterfield, a recognized leader in immuno-oncology, previously worked in Discovery Oncology at Merck and served as Vice President of Research and Development at the Parker Institute for Cancer Immunotherapy, bringing expertise in cancer vaccines, immune profiling, and cellular therapies for solid tumors. The appointment is intended to support Epitopea as it advances its lead candidate CryptiVax™-1001, an RNA-based immunotherapy for high-grade serous ovarian cancer, toward clinical development.